Back to Results
First PageMeta Content
Cannabinoids / Pharmaceuticals policy / Antiemetics / Food and Drug Administration / Investigational New Drug / Epilepsy / Medical cannabis / Cannabidiol / Expanded access / Medicine / Health / Pharmacology


Comes Now Epidiolex™ (FDA approves IND studies of CBD) By Fred Gardner October 22, 2013 In response to urgent need expressed by parents of children with intractable epilepsy, the U.S. Food and Drug Administration is al
Add to Reading List

Document Date: 2013-12-09 08:37:29


Open Document

File Size: 243,43 KB

Share Result on Facebook

City

New York / /

Company

GW Pharmaceuticals / /

Country

United States / United Kingdom / /

/

Event

FDA Phase / Product Recall / Product Issues / /

Facility

University of Reading / /

IndustryTerm

“site / manufacturing / treatment protocol / /

MedicalCondition

inflammatory process / seizures / neurological disorders / intractable epilepsy / pediatric epilepsy / oxygen starvation / different seizure disorders / seizure / inflammatory encephalitis / epilepsies / pain / each seizure / Multiple Sclerosis / next seizure / epilepsy / inflammation / immediately lifethreatening diseases / re having continuing seizures / /

MedicalTreatment

treatment protocol / /

Organization

Center for Integrative Neuroscience and Neurodynamics / Congress / NYU School of Medicine / U.S. Food and Drug Administration / FDA / University of Reading / NYU / /

Person

Geoffrey Guy / Roberta Cilio / Fred Gardner / Ben Whalley / Orrin Devinsky / /

Position

chairman / correspondent / would-be investigator / physician / Medical Director at medicaldirector@gwpharm.com / /

Product

anti-epileptic medicines / Good-Manufacturing-Practices medication / Epidiolex™ / Epidiolex / CBD / /

ProvinceOrState

Indiana / /

Technology

Neuroscience / treatment protocol / /

SocialTag